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GABAA receptors mediate fast inhibitory neurotransmission in the brain. Dysfunction of
these receptors is associated with various psychiatric/neurological disorders and drugs
targeting this receptor are widely used therapeutic agents. Both the efficacy and plasticity
of GABAA receptor-mediated neurotransmission depends on the number of surface
GABAA receptors. An understudied aspect of receptor cell surface expression is the
post-translational regulation of receptor biogenesis within the endoplasmic reticulum
(ER). We have previously shown that exogenous GABA can act as a ligand chaperone
of recombinant GABAA receptors in the early secretory pathway leading us to now
investigate whether endogenous GABA facilitates the biogenesis of GABAA receptors
in primary cerebral cortical cultures. In immunofluorescence labeling experiments, we
have determined that neurons expressing surface GABAA receptors contain both GABA
and its degradative enzyme GABA transaminase (GABA-T). Treatment of neurons with
GABA-T inhibitors, a treatment known to increase intracellular GABA levels, decreases
the interaction of the receptor with the ER quality control protein calnexin, concomittantly
increasing receptor forward-trafficking and plasma membrane insertion. The effect of
GABA-T inhibition on the receptor/calnexin interaction is not due to the activation of
surface GABAA or GABAB receptors. Consistent with our hypothesis that GABA acts as
a cognate ligand chaperone in the ER, immunogold-labeling of rodent brain slices reveals
the presence of GABA within the rough ER. The density of this labeling is similar to that
present in mitochondria, the organelle in which GABA is degraded. Lastly, the effect of
GABA-T inhibition on the receptor/calnexin interaction was prevented by pretreatment
with a GABA transporter inhibitor. Together, these data indicate that endogenous GABA
acts in the rough ER as a cognate ligand chaperone to facilitate the biogenesis of
neuronal GABAA receptors.
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Introduction
The neurotransmitter γ-aminobutyric acid (GABA) is the main
inhibitory neurotransmitter in the central nervous system.
Approximately 30% of synapses in the brain contain GABAA
receptors (Nutt, 2006), a subtype of GABA receptor that mediates
fast inhibitory neurotransmission. Upon binding GABA, an
integral chloride channel within the receptor is gated, allowing
chloride influx thus leading to membrane hyperpolarization and
neuronal inhibition. The GABAA receptor is associated with a
variety of psychiatric (anxiety, schizophrenia) and neurological
(epilepsy, insomnia) disorders (Möhler, 2006; Charych et al.,
2009). Importantly, the receptor is the target of several classes
of widely used therapeutic agents including benzodiazepines,
barbiturates and anesthetics (Whiting, 2003).
GABAA receptors belong to the Cys-loop ligand-gated ion
channel superfamily, whose other members include the nicotinic
acetylcholine, glycine and serotonin type 3 receptors (Olsen
and Sieghart, 2008). Cys-loop ligand-gated ion channels are
pentameric in structure, with each subunit possessing a large
extracellular N-terminus, four membrane-spanning domains
(M1–M4), a large cytoplasmic loop between M3 and M4,
and a short extracellular C-terminus. Although 19 GABAA
receptor subunits have been identified only a limited number of
receptor subtypes exist based on developmental/tissue expression
and assembly residues that specify oligomerization interfaces
(Olsen and Sieghart, 2009). The various receptor subtypes
display distinct functional characteristics, cellular/subcellular
distributions, pharmacology, protein/protein interactions and
posttranslational modifications. The predominant receptor
subtype in brain is composed of α1β2γ2 subunits, with two
copies of α1 and β2 subunits (McKernan and Whiting, 1996).
Two GABA binding sites are present on each pentamer, with
the GABA binding pocket formed at the αβ subunit interfaces
by subunit N-terminal regions (Amin and Weiss, 1993). Of
particular relevance to the present study, the receptor topology
places the GABA binding pocket within the lumen of the RER
during receptor biogenesis.
Given that the concentration of synaptically-released GABA
is often saturating for postsynaptic receptors, the efficacy
and plasticity of fast GABAergic neurotransmission is largely
determined by the number of GABAA receptors expressed
at the cell surface (Otis et al., 1994; Nusser et al., 1997).
Recognizing this, numerous studies have been directed toward
understanding the processes that regulate GABAA receptor cell
surface expression including exocytosis, lateral diffusion, surface
stabilization, endocytosis, recycling and degradation (reviewed
in Luscher et al., 2011). Despite extensive investigation of
these processes, little is known regarding post-translational
mechanisms in the RER that regulate GABAA receptor surface
levels.
Emerging evidence suggests that the RER functions as
a reservoir for integral membrane proteins from which
inactive nascent pools can be repartitioned into functional
pools (Breitwieser, 2014; Leidenheimer and Ryder, 2014).
Consistent with this concept, pharmacological chaperones act
post-translationally in the RER to facilitate the biogenesis,
and subsequent trafficking and function of their target
proteins (Bernier et al., 2004; Ulloa-Aguirre and Michael
Conn, 2011; Breitwieser, 2014; Leidenheimer and Ryder,
2014; Srinivasan et al., 2014). While the majority of studies
investigating pharmacological chaperones have examined their
ability to rescue the biogenesis of RER-retained, disease-
causative mutants, pharmacological chaperones also promote
the biogenesis of inefficiently processed wild type proteins
such as δopioid (Petäjä-Repo et al., 2002; Chen and Liu-Chen,
2009), β-adrenergic (Kobayashi et al., 2009), dopamine D4
(Van Craenenbroeck et al., 2005), and nicotinic acetylcholine
(Kuryatov et al., 2005; Sallette et al., 2005; Srinivasan et al.,
2011) receptors. The ability of exogenous ligands to act
as ligand chaperones in the RER raises the question of
whether endogenous ligands may function as ‘‘cognate ligand
chaperones’’ to regulate the biogenesis of their receptors.
It has been suggested that such regulation may occur for
choline/nicotinic acetylcholine receptors (Sallette et al., 2005),
growth hormone/growth hormone receptors (van den Eijnden
and Strous, 2007), GABA/GABAA receptors (Eshaq et al., 2010)
and adenosine/A1-adenosine receptors (Kusek et al., 2015).
Furthermore, based on the observation that glutamate receptors
with mutated glutamate binding domains are retained in the
RER, it has been suggested that glutamate occupancy of nascent
glutamate receptors may be required for efficient biogenesis
of NMDA, kainate and AMPA glutamate receptors (Grunwald
and Kaplan, 2003; Mah et al., 2005; Valluru et al., 2005; Fleck,
2006; Penn et al., 2008; Coleman et al., 2009, 2010; Gill et al.,
2009; Kenny et al., 2009; She et al., 2012). The present work
extends our previous findings that exogenous GABA acts as
a ligand chaperone of recombinant GABAA receptors (Eshaq
et al., 2010) by investigating whether native GABAA receptors in
primary neuronal cultures undergo cognate ligand chaperoning
by endogenous GABA.
Methods
Drugs
Vigabatrin, picrotoxin and valproic acid were obtained from
Sigma. NCC 05-2090 HCl and R-(+) baclofen HCl were obtained
from Tocris and Santa Cruz Biotechnology, respectively.
Primary Cortical Neuronal Cultures
Timed-pregnant Sprague-Dawley rats (Harlan or Charles River)
were singly housed in an AALACC approved facility. Primary
cerebral cortical neuronal cultures were prepared from E18
embryos. Experimental procedures were approved by the
Animal Care and Use Committee of LSU Health Sciences
Center-Shreveport in accordance with NIH guidelines. To
prepare primary cerebral cortical cultures, cerebral cortices were
dissected from E18 brains, minced in calcium/magnesium free
Hank’s balanced salt solution (HBSS) (Invitrogen), triturated in
HBSS containing 0.05 mg/ml deoxyribonuclease I (Sigma), and
incubated for 15 min in trypsin-EDTA solution (Invitrogen)
at 37◦C. Dissociated neurons were gently pelleted, resuspended
in Neurobasal medium (Invitrogen) containing 10% heat-
inactivated fetal bovine serum (FBS, Atlanta Biologicals), filtered
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through sterile gauze, supplemented with 10% FBS and plated
on 35 mm poly-D-lysine-coated plates at a density of either
2,500,000 cells/plate (high-density) or 250,000 cells/plate (low-
density, glass-bottom insert dishes, Mattek) and cultured at 37◦C
in a humidified atmosphere of 95% air and 5% CO2. For high-
density neurons, at days in vitro (DIV) 3, 10 µM β-cytosine
arabinoside (ARC, Sigma) was added to the culture medium to
inhibit glial cell proliferation. For low-density cultures, medium
was replaced 3 h post-plating with serum-free Neurobasal
medium supplemented with B-27 (Invitrogen). For low-density
neurons, a quarter media change with glial-conditioned serum-
free medium supplemented with 10 µM ARC was performed at
DIV 3. Low-density cultures were fed thereafter once per week
with glial-conditioned serum-free medium. Neuronal cultures
were used for experiments between DIV 12–15.
Immunofluorescence Labeling and Confocal
Microscopy
Double-Labeling Experiments for Detection of GABA
or GABA-T in Cells Expressing Surface GABAA
Receptors
Living low-density neurons were incubated with a mouse
monoclonal anti-β2/3 subunit antibody (1:100, Millipore, clone
62–3G1) for 1.5 h at room temperature. Cells were then fixed
in 4% paraformaldehyde, permeabilized with Triton X-100 (5%)
and incubated with a highly-adsorbed Alexa 594-conjugated
donkey anti-mouse antibody (1:1000, Invitrogen). Neurons were
then blocked with 10% FBS and incubated overnight with either
a rabbit polyclonal anti-GABA (1:1000, Sigma) or anti-GABA
transaminase (1:100, 4-aminobutyrate aminotransferase ABAT;
Proteintech) antibody. An Alexa 488-conjugated donkey anti-
rabbit antibody (1:1000, Invitrogen) was used for the detection
of primary antibodies.
Receptor Insertion Protocol
Living low-density neurons were incubated with a mouse
monoclonal anti-β2/3 subunit antibody (1:100, Millipore, clone
62–3G1) for 1.5 h at room temperature. Room temperature
incubations allow receptor insertion into the plasma membrane
(Lu et al., 2001; Sun et al., 2005) but not endocytosis
(Machu et al., 2006) and Figure 4C. Cells were then fixed
(4% paraformaldehyde), permeabilized (5% Triton X-100) and
incubated with a highly-adsorbed Alexa 594-conjugated donkey
anti-mouse antibody (1:1000, Invitrogen).
Receptor Endocytosis Protocol
Living neuronal cultures were incubated with mouse monoclonal
anti-β2/3 subunit antibody for 1.5 h at either 37◦C or room
temperature. Neurons were then placed on ice and incubated
in a donkey anti-mouse secondary antibody (1:1000) for 1 h.
to detect surface receptors that remained on the cell surface
during the primary antibody labeling step. Cells were then fixed
in 4% paraformaldehyde and permeabilized with 5% Triton X-
100. To detect receptors that had undergone endocytosis during
the primary antibody labeling period, internalized receptor
was detected with a donkey anti-mouse secondary antibody
conjugated to Alexa 594.
Image Acquisition and Analysis
Images for the above experiments were acquired using a Leica
DMI 6000 CS inverted laser-scanning confocal microscope
(argon/krypton laser) with a Plan Apo 63x/glycerol immersion
objective. The laser intensity, photomultiplier gain, and iris
were optimized for each experiment and kept constant
within that experiment. A Z-series of twenty optical sections
(0.2 µm/section) was collected to capture three dimensional
information and the series was reconstructed to yield images.
For the insertion experiments, the images were analyzed using
NIH ImageJ 1.43 software. For each image, the anti-β2/3 subunit
fluorescence signal was analyzed for fluorescence intensity,
number of puncta and puncta size (range 0.1–2.5 µm). Each
experiment was performed in triplicate with at least two images
acquired for each triplicate dish to yield six images for each
experimental condition per experiment. All quantified data
were acquired and analyzed by an investigator blinded to the
experimental treatments.
Coimmunoprecipitation Experiments
High-density neuronal cultures were treated at 37◦C with
drugs (vigabatrin, picrotoxin, NCC 05–2090 HCl, baclofen
or valproic acid) at concentrations and treatment times
indicated in the results section. Following treatment, cells
were harvested in RIPA buffer (Tris-HCl 50 mM, pH, 7.4;
NaCl 150 mM, 0.5% sodium deoxycholate, 1% NP-40, 0.1%
SDS and EDTA 5 mM) containing protease inhibitor cocktail
(Roche Diagnostics), sonicated, centrifuged at 16,000 × g for
10 min, and the protein concentration of the supernatant
determined using a bicinchoninic protein assay kit (Pierce).
To immunoprecipitate the GABAA receptor α1 subunit or
insulin receptor β chain under nondenaturing conditions,
500 µg of protein lysate was incubated overnight at 4◦C with
2 µg of either polyclonal rabbit anti-α1 subunit antibody (α1
N(1–9), generously provided by Dr. Werner Sieghart, Medical
University of Vienna), rabbit monoclonal anti-insulin receptor
β chain antibody (Cell Signaling Technology) or control IgG
(Figure 2E) and 40 µl of protein A Agarose beads (1:1 slurry)
(Millipore). Immunoprecipitated samples were pelleted, washed
and resuspended in Laemmli sample buffer. Neuronal lysates
and immunoprecipitates were each resolved by SDS-PAGE and
transferred to polyvinylidene fluoride membranes (Millipore).
Membranes were incubated with either polyclonal rabbit GABAA
receptor anti-α1 subunit (1:1000, Phosphosolutions), polyclonal
rabbit anti-calnexin (1:1000, Enzo Life Sciences), monoclonal
mouse anti-actin (Abcam) or rabbit monoclonal anti-insulin
receptor β chain (Cell Signaling Technology) antibody overnight
at 4◦C followed by incubation with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories). In order to detect the 50 kDa
receptor α1 subunit without interference from the 50 kDa IgG
heavy chain of the immunoprecipitating antibody, a light chain-
specific secondary antibody was used (Figure 2E). HRP activity
was detected by enhanced chemiluminescence (Pierce kit) using
film. Film exposure times were adjusted to yield band intensities
in the linear range. The integrated density volumes (IDVs, i.e.,
pixel intensity × mm2) of each band was measured using NIH
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Image J 1.43 software. IDVs obtained from regions adjacent
to the bands of interest were used for background subtraction.
Lysate data were normalized to actin.
Glycosidase Digest Experiments
Anti-α1 subunit antibody immunoprecipitations were
performed as described above. Immunoprecipitates from
each condition (control and VGB-treated) were divided equally
into three tubes for either mock-treatment (undigested), or
digest with either Endo H or PNGase. Immunoprecipitates
were then denatured at 100◦C for 3 min and digested for 2 h at
37◦C with 0.005 units/µl of Endo-β-N-acetylglucosaminidase
H (Endo H, Sigma) in sodium citrate buffer (50 mM sodium
citrate, pH = 5.5, 1% Triton X-100, 0.1% SDS, 50 mM β-
mercaptoethanol) or 500 units/µl Peptide-N-glycosidase
F (PNGase, New England Biolabs) in Tris buffer (50 mM
Tris-HCl, pH = 7.4, 1% Triton X-100, 0.1% SDS, 50 mM β-
mercaptoethanol). Additional samples were mock digested (no
enzyme, i.e., ‘‘undigested’’). Laemmli buffer was then added
to each sample, samples were boiled and subjected to SDS
PAGE/Western blotting with an anti-α1 subunit antibody
(1:1000, Phosphosolutions) and a light chain-specific, HRP-
conjugated secondary antibody.
DAB and Immunogold GABA Double Labeling
and Electron Microscopy
Mice (C57 Bl/6J, males, 12 weeks old, Jackson Labs, Bar Harbor,
ME) were used for these experiments. Handling and care of
mice was consistent with federal guidelines of the Public Health
Service Policy on the Humane Care and Use of Laboratory
Animals and this protocol was approved by the Portland VA
IACUC. Retrograde tracing to localize glutamate-containing
neurons in the motor cortex was performed by biotinylated
dextran amine (BDA) injections into the underlying dorsolateral
striatum. A 10% solution of 3 kDa BDA (Lysine Fixable: BDA-
3000; Life Technologies, Eugene, OR) was prepared in 0.1 M
sodium citrate-HCl (pH 3.0), as described by Reiner et al.
(2000). Mice were anesthetized with isoflurane and positioned
in a stereotaxic frame (Kopf Instruments, Tujunga, CA). The
dorsolateral quadrant of the striatum (AP +1.0 mm, ML
+2.0 mm, DV −3.0 mm) (Paxinos and Franklin, 2004) was
infused with 200 nl of BDA using a Nanoject II (Drummond
Scientific, Broomall, PA) apparatus for delivery of the tracer.
Mice were euthanized by transcardial perfusion with 2.5%
glutaraldehyde/0.5% paraformaldehyde/0.1% picric acid in 0.1M
phosphate buffer (pH 7.3) 1 week after surgery to allow for
retrograde transport of the BDA to the overlying motor cortex
neurons. Brains were removed, cut in half coronally at the level
of the hypothalamus and the rostral half, containing the BDA
infused striatum was placed in a microwave tissue processing
unit (Pelco BioWave, Ted Pella, Inc., Redding, CA) containing
a temperature controlled fixation bath using a thermoelectric
recirculating chiller (Pelco Steady Temp Pro, Ted Pella Inc) for
a total of 60 min (30 min., 150 watts(W) at 28◦C; 15 min.,
150 W at 25◦C; 15 min., 650 W at 25◦C). The brain was then
rinsed and left in 0.1 M phosphate buffer (PB) at 4◦C for
overnight. Following vibratome (Leica Microsystems, Buffalo
Grove, Il) sectioning (60 µm) and collection of motor cortex
slices [equivalent to: +0.5 to +2.0 mm; (Paxinos and Franklin,
2004), the tissue was then processed in the microwave oven for
localization of the BDA tracer using diaminobenzidine (DAB)
histochemistry. The tissue was exposed to an Avidin/Biotin
enzyme complex (ABC), (Vector Laboratories Burlingame, CA)
under constant vacuum, with a temperature limit of 30◦C for
a total of 15 min (3’ at 150 W; 4’ at 0 W; 3’ at 150 W;
5’ at 150 W). Following one rinse with phosphate buffered
saline (PBS) and one with the imidazole buffer (25 mls of
0.2 M imidazole, pH 9 + 79 mls of 0.1 M sodium acetate,
in 396 mls water) (1 min. each at 100 W, and temp. limit
of 30◦C), the tissue was exposed to DAB [5 mg/10 mls of
imidazole buffer + 2 µl of 30% H2O2 just prior to use)
for 10 min., constant vacuum, 150 W and a temperature
limit of 30◦C. This was then followed by 1 final rinse with
imidazole buffer and then PBS (1 min. each at 100 W, and
temp. limit of 30◦C). The tissue was then processed in the
microwave oven (Pelco BioWave, Ted Pella, Inc, Redding, CA)
and embedded in epoxy as previously described (Schang et al.,
2010;Walker et al., 2012). Post-embedding immunogold electron
microscopy was performed according to previous methods
with modifications (Phend et al., 1992; Meshul et al., 1994;
Schang et al., 2010). Thin sections (60–80 nm) were cut using
an ultramicrotome (UltracutE, Leica, Microsystems, Buffalo
Grove, Il). The GABA antibody (non-affinity purified, rabbit
polyclonal; Sigma Chemical Co., St. Louis, MO), as previously
characterized (Phend et al., 1992), was diluted 1:250 in TBST
pH 7.6 and applied to the thin sections overnight. We previously
reported that incubation of this antibody with 3 mM GABA
resulted in no immunogold labeling, showing the specificity
of the GABA labeling (Meshul et al., 1994). A goat anti-
rabbit IgG secondary antibody to detect the primary antibody,
tagged with 12 nm gold particles (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA) was diluted 1:25 in TBST
pH 8.2 and incubated for 90 min with the thin section. After
washing the grids twice in TBST 8.2 and then water, the
thin sections were counterstained with uranyl acetate and lead
citrate. Photographs of DAB labeled neurons within Layer V
of the motor cortex were randomly taken. A total of ten DAB
neurons were photographed and gold particles were counted
within the same cells for the RER (intraluminal and membrane
associated), mitochondria (inside andmembrane associated) and
cytoplasm (outside of organelles) using ImagePro Plus Imaging
program (Media Cybernetics, Rockville, MD). The density of
gold particles/µm2 was then calculated and compared between
the various subcellular compartments.
Results
Neurons Expressing Surface GABAA Receptors
Contain the Neurotransmitter GABA and its
Degradative Enzyme GABA Transaminase
For GABA to act as a ligand chaperone, GABA must be
present in neurons that express surface GABAA receptors.
While GABA would be expected to be present in boutons
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of GABAergic neurons, we sought to determine whether
GABA would be more widely distributed throughout neurons.
To determine whether this is the case, immunofluorescence
experiments were conducted in which primary cerebrocortical
cultures were dually-labeled for the presence of surface
GABAA receptors and GABA. To label GABAA receptors,
an anti-β2/3 subunit antibody was used that recognizes an
extracellular epitope common to both β2 and β3 subunits.
Of the three β subunit isoforms, mature cortical neurons
contain predominantly β2 and β3 subunits (Pirker et al., 2000),
therefore an anti-β2/3 subunit antibody would presumably
detect the majority of GABAA receptors present in the cultures.
For these experiments, surface anti-β2/3 subunit labeling was
performed to ensure the measurement of pentameric receptors.
Consistent with the literature (Craig et al., 1994), surface anti-
β2/3 subunit staining was observed on the cell soma and
throughout the processes (Figures 1A,B). Importantly, anti-
GABA staining was observed throughout the soma and proximal
dendrites of neurons expressing surface GABAA receptors
(Figures 1A,B). Approximately 55% of β2/3 immunopositive
cells were immunopositive for GABA, with the intensity of
the GABA signal varying between cells. The anti-GABA signal
was distributed throughout the processes (Figure 1A) and was
sometimes colocalized with receptor puncta (Figure 1B). The
intensity of GABA immunoreactivity in the cell soma of neurons
expressing the receptor was uniformly lower than that observed
in the processes (Figure 1A).
We next determined whether GABA transaminase (GABA-
T), a mitochondrial enzyme that degrades GABA, was present
in neurons expressing surface GABAA receptors. GABA-T
immunoreactivity was observed in β2/3 subunit immunopositive
neurons, where it was restricted to the cell soma (Figure 1C). The
selective presence of GABA-T in the soma corresponds to the
subcellular region in which GABA immunoreactivity was noted
to be lowest.
Inhibition of GABA Transaminase Decreases the
Association between the GABAA Receptor α1
Subunit and the ER Quality Control Protein
Calnexin
Calnexin is an ER chaperone that binds to nascent proteins
as they undergo repeated folding/unfolding cycles until native
folding is achieved or terminal misfolding occurs (Araki and
Nagata, 2011). Because pharmacological chaperones facilitate the
release of their target proteins from the calnexin binding cycle
(Morello and Bichet, 2001; Fan et al., 2005; Robert et al., 2005;
Gong et al., 2006) and since calnexin is known to interact with
GABAA receptor subunits (Connolly et al., 1996; Bradley et al.,
2008), we reasoned that if GABA acts as a ligand chaperone then
manipulations that increase intracellular GABA levels should
cause the release of GABAA receptor subunits from the calnexin
quality control system.
To examine this possibility, vigabatrin (i.e., gamma-vinyl-
GABA, Sabril®), an irreversible inhibitor of GABA-T (Jung et al.,
1977) that increases GABA levels both in vivo (Löscher and
Hörstermann, 1994; Manor et al., 1996; Todd and Baker, 2008;
Tong et al., 2009) and in neuronal cultures (Gram et al., 1988;
Sonnewald et al., 2006) was used to elevate intracellular GABA
levels. Neuronal cultures were treated with vigabatrin (0.5 µg/µl,
3 h) and the receptor α1 subunit was then immunoprecipitated
using an anti-α1 subunit antibody. An anti-α1 subunit antibody
was used for the immunoprecipitation experiments since we
do not have an anti-β2/3 subunit antibody that is suitable
for immunoprecipitation experiments and the α1 subunit is
abundant in cortex (Pirker et al., 2000). Both cell lysates
and immunoprecipitates were subjected to SDS PAGE/Western
blotting using anti-α1 subunit and anti-calnexin antibodies.
Vigabatrin treatment significantly decreased the amount
of calnexin co-immunoprecipitated by the anti-α1 subunit
antibody to 60.8 ± 3.4% (average ± SEM) of vehicle-treated
controls (p ≤ 0.0005, paired t-test, n = 5) (Figures 2A,C).
FIGURE 1 | Neurons expressing surface GABAA receptors contain
both the neurotransmitter GABA and its degradative enzyme GABA
transaminase. (A) Living low-density neuronal cultures were
immunolabeled for surface GABAA receptors using an anti-β2/3 subunit
antibody, fixed, permeabilized and immunolabeled for the neurotransmitter
GABA. Surface receptors (red) are distributed throughout both the soma
and processes, whereas GABA immunoreactivity (green) is observed
throughout the neuron but most prominently in the processes. (B) An
enlarged image of a neuronal process immunolabeled as described in
(A). Note the punctate distribution of the receptor, the diffuse cytoplasmic
staining of GABA and the colocalization of GABA with some surface
receptor puncta (arrows). (C) Neuronal cultures were immunolabeled for
surface GABAA receptors using an anti-β2/3 subunit antibody, fixed,
permeabilized and immunolabeled for GABA transaminase (GABA-T)
(green). Note that GABA transaminase immunoreactivity is localized to the
cell soma.
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FIGURE 2 | Inhibition of GABA transaminase decreases the association
of the GABAA receptor α1 subunit with the ER quality control protein
calnexin. (A) High-density neuronal cultures were treated with vigabatrin
(VGB) (0.5 µg/µl, 37◦C) for 3 h. Neurons were then lysed and the α1 subunit
was immunoprecipitated under nondenaturing conditions with an anti-α1
subunit antibody. Cell lysates and immunoprecipitated samples were
subjected to SDS PAGE/Western blotting using GABAA receptor anti-α1
subunit and anti-calnexin antibodies as indicated. Shown is a representative
immunoblot. (B) Neurons were treated with valproic acid (VPA) (200 µM,
37◦C) for 3 h and processed as described in (A). Shown is a representative
immunoblot. (C) Replicate data for immunoprecipitated samples described in
(A) and (B). Immunoreactive bands were quantified densitometrically. Data are
presented as the average ± SEM. *p ≤ 0.05, paired t-test, n ≥ 3. Experiments
A and B were conducted on cultures made from different litters and t-tests
were performed on their respective controls. (D) Neurons were treated with
VGB as described in (A) and cell lysates were subjected to
immunoprecipitation with an anti-insulin receptor β chain antibody.
Immunoprecipitates were resolved by SDS PAGE and visualized by Western
blotting with anti-insulin receptor β chain and anti-calnexin antibodies. The blot
shown is representative of three independent experiments. (E) Immunoblotting
with an anti-α1 subunit antibody followed by a light-chain specific secondary
antibody was performed on neuronal lysates and samples immunoprecipitated
with either an anti-α1 subunit antibody or control IgG. No band is detected in
the IgG control lane demonstrating that the IgG light-chain specific secondary
antibody does not recognize the 50 kDa IgG heavy-chain.
Importantly, vigabatrin treatment did not affect the amount of
α1-subunit immunoprecipitated (126.1 ± 23.8% of control) or
the amounts of either the α1-subunit (107.9 ± 6.6% of control)
or calnexin (107.1 ± 7.1%) in total cell lysates. We next tested
a second GABA-T inhibitor, the anticonvulsant valproic acid
(Depakote®) (Figures 2B,C). Treatment of the neurons with
valproic acid (200 µM, 3 h) decreased the amount of calnexin
coimmunoprecipitated by the anti-α1 subunit antibody to 65.5±
8.8% (average ± SEM) of control (p ≤ 0.05, paired t-test, n = 3).
Similar to vigabatrin, valproic acid treatment did not affect the
amount of α1-subunit that was immunoprecipitated (91.4 ±
3.8%). Since both GABA-T inhibitors produced similar results,
it is likely that their ability to decrease the α1 subunit/calnexin
interaction is due to the inhibition of GABA-T rather than to off-
target effects such as histone deacetylase inhibition by VPA (Eyal
et al., 2004).
To control for non-specific effects that GABA-T inhibition
may have on secretory pathway processes, negative control
experiments were performed. The insulin receptor was used
for this purpose since it is presumed to be present in GABAA
receptor-containing neurons (Wan et al., 1997) and is known to
interact with calnexin (Bass et al., 1998). Following vigabatrin
treatment, the amount of calnexin immunoprecipitated by an
anti-insulin receptor β chain antibody was 110.5± 13.6 (average
± SEM) of the control, n = 3 (Figure 2D, representative blot)
which was not significantly different from control indicating that
inhibition of GABA-T does not cause global disruption of the
calnexin quality control system.
Vigabatrin Treatment Promotes
Forward-Trafficking of the GABAA Receptor
through the Secretory Pathway
The ability of GABA-T inhibitors to decrease the interaction
between the receptor α1 subunit and calnexin suggests that an
elevation in intracellular GABA levels may facilitate receptor
maturation and cause the release of conformationally mature
GABAA receptors from the ER quality mechanisms. If so, there
should be a corresponding increase in the forward-trafficking of
the receptor through the secretory pathway.
As glycoproteins undergo forward-trafficking through the
secretory pathway there are compartment-specific modifications
made to their N-linked glycans that can be used to monitor
anterograde glycoprotein trafficking (Freeze, 2001). N-linked
glycosylated proteins within the ER contain high-mannose
glycans (immature) that are sensitive to digest by the
Endoglycosidase H (Endo H), while those in or beyond the
trans-Golgi contain low-mannose glycans (mature) that are
resistant to Endo-H digest. Thus, Endo H digest assays can be
used to distinguish immature glycoproteins in the early secretory
pathway from mature glycoproteins.
The GABAA receptor α1 subunit contains two N-linked
glycans (Chen et al., 2012). We first examined the glycosidase
sensitivity of the α1 subunit. Neuronal cultures were lysed and
the α1 subunit was immunoprecipitated with an anti-α1 subunit
antibody. Immunoprecipitated samples were then digested with
either Endo H or N-glycosidase F (PNGase), a glycosidase
that cleaves N-linked glycans from both immature and mature
glycoproteins thus yielding complete N-linked deglycosylation.
Following glycosidase digest, samples were subjected to SDS
PAGE and Western blotting with an anti-α1 subunit antibody.
As expected, a Western blot of undigested α1 subunit resulted in
a band that migrated at a molecular mass of 50 kDa (Figure 3A).
Digest of immunoprecipitated samples with PNGase resulted
in a single band of approximately 46 kDa, consistent with the
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FIGURE 3 | Vigabatrin treatment promotes forward-trafficking of
GABAA receptors through the secretory pathway. High-density neurons
were incubated in the absence or presence of vigabatrin (VGB) (0.5 µg/µl,
37◦C) for 6 h. The GABAA receptor α1 subunit was then immunoprecipitated
from neuronal lysates. Immunoprecipitated samples from each condition were
then split into three equal samples and digested with either Endo H or PNGase
or left undigested. Samples were resolved by SDS PAGE and analyzed by
Western blotting using an anti-α1 subunit antibody. (A) A representative
Western blot. Undigested samples yielded a single band at 50 kDa. Digest
with PNGase, which removes all N-linked glycans, resulted in a 46 kDa band.
Endo H digest produced a 48 kDa band, indicating that the α1 subunit is
partially resistant to Endo H and, therefore, represents a mature (post ER) form
of the α1 subunit. (B) Replicate data for immunoblot experiments described in
(A). Data shown are the ratio of the Endo H resistant band to the undigested
band presented as average ± SEM. *p ≤ 0.05, paired t-test, n ≥ 4.
complete removal of two N-linked glycans, each approximately
2 kDa. Endo H digest resulted in a band at approximately
48 kDa, indicating that the α1 subunit is only partially sensitive to
Endo H digest. Partial digest can occur when a protein contains
multiple N-linked glycans and one (or more) high-mannose
glycan is sterically protected from processing in the secretory
pathway, thus resulting in a mature protein with both Endo
H-sensitive and Endo H-resistant glycans, as is the case for
the GABAA receptor β2 subunit (Lo et al., 2010). Curiously,
no ‘‘immature’’ bands were observed. One possible explanation
for this results is that all the α1 subunit is ‘‘mature’’. This,
however, is not the case since the ER quality control protein
is abundantly coimmunoprecipitated by an anti-α1 subunit
antibody (Figure 2). At this time we do not have an explanation
for the absence of an ‘‘immature’’ band but note that a similar
outcome in primary neuronal cultures has been reported (Nair
et al., 2013).
Because the 48 kDa band represents α1 subunits that have
acquired Golgi-mediated partial Endo H-resistance, the 48 kDa
band is the mature form of the α1 subunit. To determine
if treatment with a GABA-T inhibitor increases the forward-
trafficking of GABAA receptors, neurons were incubated in
the absence (control) or presence of vigabatrin for 6 h. This
treatment duration was chosen to allow sufficient time for
chaperoned receptors to reach the trans-Golgi compartment.
Following drug treatment, the neurons were lysed, the α1 subunit
was immunoprecipitated and immunoprecipitates were either
undigested or digested (Endo H or PNGase) and samples were
then subjected to SDS PAGE/Western blotting (Figure 3A). To
determine whether vigabatrin treatment resulted in an increase
in the amount of mature α1 subunit, a ratio of mature (48 kDa)
to total undigested (50 kDa) α1 subunit was calculated (Lo et al.,
2010). Vigabatrin treatment increased the amount of mature
α1 subunit to 141 ± 9.6% (average ± SEM) of that observed
in vehicle-treated control neurons (p ≤ 0.05, paired t-test)
(Figure 3B).
Vigabatrin Treatment Increases Membrane
Insertion of the Receptor
We next determined if vigabatrin treatment would increase
the plasma membrane expression of the receptor. Neurons
were treated with vigabatrin for 16 h and immunofluorescence
labeling of surface receptors was performed using an anti-
β2/3 subunit antibody. Live-cell immunofluorescence labeling
was conducted at room temperature since room temperature
is permissive for receptor insertion (Lu et al., 2001; Sun et al.,
2005) but not endocytosis (Machu et al., 2006) and Figure 4C.
This was important since vigabatrin treatment might promote
GABA-induced GABAA receptor endocytosis (Barnes, 1996),
potentially masking increases in receptor membrane insertion if
only cell surface expression was measured. Vigabatrin treatment
significantly increased the fluorescence intensity, number of
puncta and puncta size of surface receptors to 157 ± 9%, 176
± 14%, and 123 ± 4% of control, respectively (average ± SEM,
n = 7, p≤ 0.01, paired t-test corrected for multiple comparisons)
(Figure 4).
The Ability of Vigabatrin to Decrease the
Association of the Receptor α1 Subunit with
Calnexin is not due to the Activation of Surface
GABAA or GABAB Receptors
GABA-T inhibitors increase presynaptic GABA levels resulting
in greater synaptic GABA release, elevated synaptic GABA
concentrations, and, therefore, increased activation of surface
GABAA and GABAB receptors (Wu et al., 2001, 2003,
2007; Peng et al., 2010). Thus, it was possible that the
ability of vigabatrin to decrease the interaction between
the GABAA receptor α1 subunit and calnexin was due
downstream consequences of surface GABAA or GABAB
receptor activation.
Synaptic levels of GABA are regulated by the GABA
transporter GAT1, which transports GABA back into presynaptic
neurons following synaptic GABA release (Madsen et al., 2010).
Blockade of GAT1 results in an increase in synaptic GABA
levels (Kersanté et al., 2013) and, thus, the activation of
GABAA and GABAB receptor subtypes (Bragina et al., 2008;
Gonzalez-Burgos, 2010). We reasoned that if the vigabatrin-
mediated decrease in the α1 subunit/calnexin interaction was
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FIGURE 4 | Plasma membrane insertion of GABAA receptors is
increased by vigabatrin treatment. Low-density cultures were
incubated in the absence (control) or presence of VGB (0.5 mg/ml,
37◦C) for 18 h. Anti-β2/3 subunit antibody immunofluorescence
labeling in living cells was performed at room temperature (permissive
for receptor insertion but not for endocytosis). Immunofluorescence
was visualized by confocal microscopy. A Z-series of ten optical
sections, each 0.2 µm thick, was collected and a 3D reconstruction
was rendered. (A) Representative image. (B) Immunofluorescence
intensity, puncta size and puncta number was quantified by an
investigator blinded to the experimental conditions. Data shown are
average ± SEM, n = 7. Comparisons between control and VGB
treatment groups were made using paired t-tests corrected for
multiple (3) comparisons *p ≤ 0.01. (C) Control experiment showing
that receptor endocytosis occurs at 37◦C but not room temperature.
Living neurons were incubated in anti-β2/3 subunit antibody at either
room temperature or 37◦C to measure receptor endocytosis. After
this incubation period the surface receptor population was labeled
with Alexa 488-conjugated secondary antibody (green). Cells were
then fixed, permeabilized and the endocytosed receptors were labeled
with Alexa 594-conjugated secondary antibody (red). The brightness
and contrast settings of images for receptor endocytosis (red) were
enhanced to show that not even a faint signal is detectable at room
temperature.
due to the activation of surface GABAA or GABAB receptors,
then the inhibition of GAT1 should mimic the effect of
vigabatrin. To test this, neurons were treated for 3 h with
either DMSO (control) or NCC 05-2090 (100 µM), a non-
selective GAT blocker at the concentration used here (Madsen
et al., 2010). Immunoprecipitations were then conducted with
the anti-α1 subunit antibody and SDS PAGE/Western blotting
was performed (Figures 5A,D). The amount of calnexin
coimmunoprecipitated by the anti-α1 subunit antibody in
the NCC-treated neurons was 113.0 ± 7.6% (average ±
SEM, n = 4) of vehicle-treated controls. Thus, a treatment
known to elevate synaptic GABA levels and activate surface
GABAA and GABAB receptors does not mimic the effects of
vigabatrin.
We next determined whether the GABAB receptor
agonist baclofen would mimic the effects of vigabatrin
(Figures 5B,D). Following baclofen treatment, the amount
of calnexin immunoprecipitated by the α1 subunit was 93
± 7.6% of control (average ± SEM, n = 3) indicating that
activation of GABAB receptors does not mimic the effect of
vigabatrin on the α1 subunit/calnexin interaction. Baclofen
treatment did not affect the amount of immunoprecipitated
α1-subunit which was 97 ± 7.6% (average ± SEM) of
control.
The involvement of surface GABAA receptors was next tested.
For these experiments, we chose not to use GABAA receptor
antagonists that bind to the GABA binding site since they could
potentially act as GABAA receptor pharmacological chaperones
(Eshaq et al., 2010). Instead, we determined whether the
GABAA receptor channel blocker picrotoxin (PTX) could block
the vigabatrin-mediated decrease in the α1 subunit/calnexin
association. In these experiments PTX failed to block the
vigabatrin effect (Figures 5C,D). Treatment with vigabatrin
in the absence or presence of PTX significantly decreased
the amount of calnexin coimmunoprecipitated by the anti-
α1 antibody to 69 ± 2.1% and 64.7 ± 10%, respectively
(average ± SEM) compared to vehicle-treated controls (one-
way ANOVA followed by post hoc Tukey’s Multiple Comparison
Test, p ≤ 0.05, n = 3). No significant difference was
observed between vigabatrin and vigabatrin + PTX treatments.
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FIGURE 5 | The ability of vigabatrin treatment to decrease the
association of the receptor α1 subunit with calnexin is not due to the
activation of surface GABAA or GABAB receptors. High-density neuronal
cultures were treated for 3 h at 37◦C with (A) DMSO (control) or the GAT
blocker NCC 05-2090 (100 µM), (B) vehicle (control) or the GABAB receptor
agonist baclofen (100 µM), or (C) vehicle (control), VGB (0.5 µg/µl), VGB (0.5
µg/µl) + the GABAA receptor channel blocker PTX (100 µM) or PTX (100 µM).
Neuronal lysates were immunoprecipitated with an anti-α1 subunit antibody
and SDS PAGE/Western blotting was performed with anti-α1 subunit and
anti-calnexin antibodies. Representative blots are shown in (A–C). (D)
Replicate data (n ≥ 3) of experiments in (A–C). Neuronal cultures from
different litters were used for experiments in (A–C). Data for each experiment
were normalized to their respective controls and assembled into one graph.
Immunoreactive bands were quantified densitometrically and data are
presented as the average ± SEM. A one-way ANOVA performed on the data
set from experiments in C yielded a p value of 0.0013. Post hoc significance
differences (Tukey’s multiple comparison) between C vs. VGB and C vs. VGB
+ PTX were observed (*p ≤ 0.05). No statistically significant difference was
observed between VGB vs. VGB + PTX treatment groups.
PTX treatment alone did not affect the α1 subunit/calnexin
interaction (104.5 ± 3.2% of control, average ± SEM, n = 3).
Vigabatrin, PTX or PTX + vigabatrin treatments did not
affect the amount of α1-subunit immunoprecipitated (102.9
± 8.5%, 101.1 ± 18.5%, 101.3 ± 25.4%, average ± SEM,
of control, respectively). Collectively, these data indicate that
the ability of the GABA-T inhibitor vigabatrin to decrease
the association of the α1 subunit with calnexin is not a
downstream consequence of surface GABAA or GABAB receptor
activation.
The Ability of Vigabatrin to Decrease the
Interaction between the Receptor α1 Subunit and
Calnexin is Prevented by the GAT Inhibitor NCC
05-2090
For GABA to act as a ligand chaperone in the RER, GABA
must gain access to the RER lumen. While it is not clear how
this occurs, GABA, a zwitterionic amino acid, may require
active transport to enter the RER by either a GAT or GAT-
like transporter. To determine if such transport might be
involved in the vigabatrin effect, we tested whether the GAT
blocker NCC 05-2090 (100 µM) could block the vigabatrin
effect. Vigabatrin and vigabatrin + NCC treatments altered
the amount of calnexin immunoprecipitated by the anti-α1
subunit antibody to 48.5 ± 7.3% and 111.5 ± 14.7% of
control, respectively (average ± SEM, n = 4) (Figure 6). These
values were significantly different from each other (one-way
ANOVA, followed by post hoc Tukey’s Multiple Comparison
Test, p ≤ 0.001). The vigabatrin + NCC treatment group was
not significantly different from control. Thus, treatment with a
GAT blocker prevents the vigabatrin-mediated decrease in the α1
subunit/calnexin interaction. Neither vigabatrin nor vigabatrin +
NCC treatment significantly affected the amount of α1-subunit
that was immunoprecipitated (129 ± 17.5% and 96 ± 3.1%,
average± SEM of control, respectively).
GABA is Present within the RER Lumen
Because the GABA chaperoning hypothesis depends on the
presence of GABA in the RER lumen, we next determined
whether GABA could be detected within the RER of neurons.
For these experiments, mouse brain slices were immunogold-
labeled using an anti-GABA antibody. Gold particles were then
detected by electron microscopy (Figure 7A). Consistent with
the known subcellular distribution of GABA (Belenky et al.,
2003), immunogold-labeling was detected in the cytoplasm
and mitochondria, where GABA is synthesized and degraded,
respectively (Pinal and Tobin, 1998). Importantly, GABA
labeling was also observed within the lumen of the RER, as well
in association with the outer leaflet of the RER membrane. Of
particular note, a cluster of immunogold particles within the RER
was observed (Figure 7A inset).
FIGURE 6 | The GAT inhibitor NCC 05-2090 prevents the
vigabatrin-mediated decreases in the association of the receptor α1
subunit and calnexin. High-density neuronal cultures were treated with
vehicle (control), VGB (0.5 µg/µl), or VGB (0.5 µg/µl) + NCC 05-2090 (100
µm) at 37◦C for 3 h. Neuronal lysates were immunoprecipitated with an
anti-α1 subunit antibody and immunoprecipitates were subjected to SDS
PAGE/Western blotting with anti-α1 subunit and anti-calnexin antibodies. (A)
A representative blot. (B) Replicate data for experiments described in (A).
Immunoreactive bands were quantified densitometrically and data plotted.
Data are presented as the average ± SEM. Using a one-way ANOVA followed
by a Tukey’s Multiple Comparison Test, VGB treatment was significantly
different from both control and VGB + NCC conditions *p ≤ 0.01, n ≥ 4. No
significant difference between control and VGB + NCC conditions was
observed.
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FIGURE 7 | Electron microscopy immunogold-labeling demonstrates
the presence of GABA within the lumen of the endoplasmic
reticulum of glutamatergic cortical neurons. (A) Postembedding
immunogold-labeling of GABA in slices of mouse primary motor cortex
neurons shows GABA present within the lumen of the rough endoplasmic
reticulum (RER) in a neuron of unidentified phenotype. Intraluminal and outer
RER membrane associated GABA labeling are indicated by arrow. Inset is a
higher magnification of a cluster of GABA immunogold-labeling within the
RER lumen. Mitochondria (M) displaying dense GABA labeling. (B)
Identification of a glutamatergic neuron of the motor cortex (hand-drawn
outline) by retrograde tracing with biotinylated dextran amine (BDA) injected
into the dorsolateral striatum. (C) Representative BDA-labeled glutamatergic
neuron showing postembedding immunogold GABA labeling of the RER in
the cell soma (D) Representative BDA-labeled glutamatergic neuron showing
postembedding immunogold GABA labeling of mitochondria (M) in the cell
soma. (E) Replicate data from multiple tissue sections from BDA-labeled
glutamate neurons analyzed for the density of immunogold GABA labeling
of various subcellular compartments (average ± SEM, n ≥ 31). Gold
particle densities in the RER and mitochondria were each significantly
greater than that in cytoplasm (*Tukey-Kramer HSD, p ≤ 0.0001).
GABA is Present within the RER Lumen of
Glutamatergic Pyramidal Neurons in the Motor
Cortex
Our initial EM experiments did not identify the type of neuron
(i.e., GABAergic interneuron, glutamatergic pyramidal neuron,
cholinergic etc.) in which GABA was detected in the RER. Since
GABAA receptors are largely postsynaptic (Luscher et al., 2011)
and present on glutamatergic neurons (Nusser et al., 1996, 1998;
Nyíri et al., 2001; Brickley and Mody, 2012), we next determined
if GABA could be found within the RER of glutamatergic
neurons of themotor cortex. These neurons were identified using
retrograde tracing by the injection of biotinylated dextran amine
(BDA) into the dorsolateral striatum (Figure 7B). Glutamatergic
motor cortex neurons displayed immunogold GABA labeling
associated with both the outer face of the RER membrane and
within the RER lumen, as well as within mitochondria and
cytoplasm (Figures 7C,D). The densities of GABA labeling of
the RER, cytoplasm and mitochondria were 131.8 ± 6.2, 22.3
± 5.6, and 129.8 ± 4.2 particles/µm2 (average ± SEM, n ≥ 31),
respectively (Figure 7E). These densities were significantly
different (ANOVA, p ≤ 0.0001). Gold particle densities in the
RER and mitochondria were each significantly greater than that
in cytoplasm (Tukey-Kramer HSD, p ≤ 0.0001). The densities
of GABA labeling in the RER and mitochondria were not
significantly different from each other, suggesting that GABA is
present in these two organelles at similar concentrations.
Discussion
Previously we demonstrated that the neurotransmitter GABA
acts as a ligand chaperone in the early secretary pathway to
promote the biogenesis of recombinant GABAA receptors (Eshaq
et al., 2010). In the present study we extend these findings using
primary neuronal cultures to show that endogenous GABA acts
as a cognate ligand chaperone for neuronal GABAA receptors.
Evidence in support of this conclusion includes the presence
of both GABA and GABA-T in GABAA receptor-containing
neurons and the observation that drug treatments (GABA-T
inhibitors) that elevate intracellular GABA levels decrease the
interaction of the receptor with the RER quality control protein
calnexin, and subsequently promote the forward-trafficking and
membrane insertion of the receptor. The effect of GABA-T
inhibitor treatment is neither due to the activation of surface
GABAA/B receptors nor is it a general effect on secretory system
processing. Lastly, immunogold detection of GABA in the RER
lumen provides key evidence in support of the chaperoning
hypothesis.
For GABA to act as a chaperone for GABAA receptors, GABA
must be present in neurons that synthesize the receptor. In our
primary cortical cultures, approximately 55% of the GABAA
receptor-positive neurons were observed to possess GABA
immunofluorescence labeling. Since only 20–30% of cortical
neurons are thought to be GABAergic (Markram et al., 2004) and
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we have not intentionally enriched our cultures for interneurons,
it is likely that non-GABAergic neurons in our culture contain
GABA as is known to occur in cerebellar neuronal cultures
(Suñol et al., 2010). We suggest that chaperoning may occur
in neurons of various phenotypes (GABAergic interneurons,
glutamatergic pyramidal neurons, etc.). Such a notion is
consistent with our ability to detect chaperoning by biochemical
methods. Although we have not yet characterized the type of
neurons in which chaperoning occurs, our study shows that
GABA is present in the RER of glutamatergic pyramidal cells, a
neuron type rich in postsynaptic GABAA receptors (Nusser et al.,
1996, 1998; Nyíri et al., 2001; Brickley andMody, 2012). The idea
that GABA may chaperone GABAA receptors in glutamatergic
neurons may seem unexpected, however, others have noted that
glutamatergic granule cells contain GABA, GAD67 and GABA
transporters (Ramírez and Gutiérrez, 2001; Bergersen et al., 2003;
Sirvanci et al., 2005; Suñol et al., 2010; Sperk et al., 2012; Ruiz
and Kullmann, 2013; Root et al., 2014) and it is possible that
other types of glutamatergic neurons may also contain GABA
and GABAergic proteins.
Calnexin is an ER resident lectin that interacts
with monoglucosylated N-linked glycans within nascent
glycoproteins to aid in their folding (Araki and Nagata, 2011).
Calnexin quality control is a dynamic process whereby protein
intermediates undergo multiple binding/unbinding cycles until
either a native structure is attained or proteins are targeted
for degradation. It is well established that pharmacological
chaperones facilitate the release of their target proteins from
the calnexin binding/unbinding cycle and that this release
is accompanied by an increase in forward-trafficking and
membrane insertion (Morello and Bichet, 2001; Fan et al., 2005;
Robert et al., 2005; Gong et al., 2006). Similarly, we show that
increases in intracellular GABA levels (via GABA-T inhibition)
decrease the association of GABAA receptor α1 subunit with
calnexin while promoting receptor forward-trafficking and
membrane insertion. This effect is not due to a general effect on
secretory pathway processing since inhibition of GABA-T does
not affect the association of calnexin with the insulin receptor
β chain. Furthermore, the effect is not due to the activation of
surface GABAA or GABAB receptors since it is neither mimicked
by the activation of surface GABA receptors nor blocked by the
GABAA receptor channel blocker picrotoxin.
Since the topology of the GABAA receptor places the GABA
binding sites within the RER lumen, GABA must access the
RER lumen to act as a cognate ligand chaperone. Our electron
microscopy immunogold-labeling experiments in cortical slices
show that GABA is present both within the RER lumen and
associated with the outer face of the RERmembrane. This finding
is consistent with GABA labeling over the Golgi apparatus of
rat suprachiasmatic nucleus neurons (Belenky et al., 2008), and,
although not described by the authors, RER luminal GABA
labeling (Figure 13 in Belenky et al. (2008)). Interestingly,
electron microscopy immunogold-labeling experiments show
that not only is GABA present within the RER lumen of
pancreatic β cells, but that RER GABA levels are dynamically
regulated by drug treatment in an organelle-specific manner
(González del Pliego et al., 2001). Such findings, coupled with
those of the present study, support a physiological role for GABA
in the RER lumen. Whether GABA and GABAA receptors are
colocalized in the RER of neurons remains to be determined,
as does whether manipulation of GABA levels by GABA-T
inhibitors affects GABA distribution in the RER.
While our experiments do not measure the absolute
concentration of GABA in the RER, intracellular GABA
concentrations have been estimated to be in the low mM
range (Otsuka et al., 1971; Rothman et al., 1993; Wu et al.,
2007). Our electron microscopy data show that the density of
GABA immunogold labeling in the RER and mitochondria is
approximately six times that of the cytoplasm. This suggests
that GABA concentrations in the RER are likely to be sufficient
for chaperoning to occur since the GABA EC50s for GABAA
receptors are in the low µM range. We should point out,
however, that the GABA binding affinity of nascent receptors
(α/β dimers or higher order oligomers) may different from that
of surface receptors. Furthermore, it is not clear how the gel-like
matrix of the RER intraluminal environment may affect GABA
binding.
An important unanswered question is how GABA accesses
the ER lumen. While it is possible that GABA may enter the
ER through open translocons following ribosomal dissociation
(Lizák et al., 2008) or via passive diffusion through a ‘‘leaky’’
ER membrane (Le Gall et al., 2004), we consider this unlikely
since the density of GABA labeling in the RER is approximately
six times that of the cytoplasm. Because the density of GABA
labeling in the RER is similar to that in mitochondria, an
organelle for which GABA is actively transported (Passarella
et al., 1984; Berkich et al., 2007), we suggest that GABA is actively
transported into the RER. Such transport would potentially
provide control over intraluminal GABA concentration. It is
conceivable that the high density cluster of GABA labeling
that we observed in the RER may represent a site of specific
uptake.
It is possible that GABA may be actively transported into the
ER by one of the four known high-affinity GABA transporters
(GAT1–3 and BGT1) (Madsen et al., 2010; Zhou and Danbolt,
2013). Although we do not know if GATs can transport GABA
into the RER, our data show that the vigabatrin-mediated
decrease in the α1 subunit/CNX interaction is blocked by a
GAT inhibitor used at a concentration that inhibits all GAT
isoforms. As integral membrane proteins, GATs are at least
transiently present in the RER and might function during their
RER residency, as is the case for glucose transporters (Takanaga
and Frommer, 2010). Additionally, GATs in isolated RER
membrane vesicles exhibit functional properties similar to GATs
at the plasma membrane (Scholze et al., 2002). Furthermore, the
intracellular concentrations of sodium and GABA, as well as the
estimated ER membrane potential, appear to offer a favorable
driving force for GAT-mediated reverse transport of GABA
into the ER (Eshaq et al., 2010). Based on the cell-type specific
distributions of GAT isoforms and the heterogeneity of cell-types
expressing the various GABAA receptor subtypes (Madsen et al.,
2010; Suñol et al., 2010; Schousboe et al., 2013), it is conceivable
that different GAT isoforms could reverse transport GABA into
the RER depending on cell-type.
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Alternatively, a non-GAT mechanism may transport GABA
into the RER. Because little is known regarding transporters that
maintain the RER environment (Csala et al., 2007; Takanaga and
Frommer, 2010), any attempts to identify a putative RER GABA
transporter will likely be challenging. In this regard, it has been
recognized for many decades that GABA enters mitochondria
to be degraded by GABA-T. Surprisingly, however, the identity
of the mitochondrial GABA transporter remains elusive despite
long-standing evidence of its existence (Passarella et al., 1984;
Berkich et al., 2007) and the identification of numerous
mitochondrial SLC25 family members (Gutiérrez-Aguilar and
Baines, 2013; Rudnick et al., 2014). Transport of GABA into
the mitochondria of the plant Arabidopsis thaliana has recently
been demonstrated to be mediated by AtGABP (Michaeli et al.,
2011), a GABA permease with sequence homology to the amino
acid-polyamine-organocation (APC) superfamily. Other GABA
permeases, transporters or carriers include the glutamate/GABA
antiporter in E. Coli used for acid resistance (Ma et al.,
2013) and three GABA permeases/transporters in Saccharomyces
cerevisiae (Kamei et al., 2011; Cao et al., 2013). A basic local
alignment search tool (BLAST) analysis reveals that none of the
abovementioned GABA carriers/transporters are homologous to
GATs. Each, however, shares homology with the L-type amino
acid transporter (LAT2), the light subunit for 4F2hc. LAT2 is a
neutral/zwitterionic amino acid transporter whose mRNA and
protein is present in many tissues including brain (Pineda et al.,
1999; Cajigas et al., 2012; Zieli n´ska et al., 2014). The substrate
Kms of LAT2 are in the micromolar range, well within the affinity
range needed to transport cytoplasmic GABA which is present at
low millimolar intracellular concentrations within both neurons
(Otsuka et al., 1971; Rothman et al., 1993; Wu et al., 2007) and
astrocytes (Lee et al., 2011).
The molecular mechanism by which GABA acts as a
ligand chaperone remains to be determined. Pharmacological
chaperones have been observed to stabilize protein structure,
release mature receptors from ER quality control mechanisms,
promote oligomerization of multimeric proteins, and facilitate
ER export (reviewed in Leidenheimer and Ryder, 2014). Because
none of these mechanisms is mutually exclusive, all could be
envisioned to apply to GABA chaperoning of GABAA receptors
as steps along a serial pathway of maturation and export. The
GABAA receptor is a heteropentamer with a stoichiometry of
αβαβγ/δ subunits forming a central chloride pore (Luscher
et al., 2011). Two orthosteric GABA binding sites are contained
within the receptor, one at each αβsubunit interface (Amin
and Weiss, 1993) with the minimum requirement for GABA
binding to an αβ heterodimer. While it is not known whether
the chaperoning effect of GABA promotes the assembly process
or occurs following pentamerization, nicotine chaperoning of
nicotinic acetylcholine receptors occurs prior to pentamerization
and facilitates subsequent oligomerization steps (Srinivasan
et al., 2011; Mazzo et al., 2013). In this light, we propose
that GABA binds to an αβ heterodimer, or higher-order
receptor intermediate, resulting in conformational changes that
lower the energy barrier for further oligomerization steps. In
support of this idea, key GABA binding residues on the α1
subunit (Boileau et al., 1999) are in close proximity to residues
involved in receptor assembly (Taylor et al., 2000; Sarto et al.,
2002; Bollan et al., 2003). Alternatively, GABA binding to
pentameric receptors may produce structural alterations that
release the receptor from ER quality control proteins and/or
expose export signals. In any case, chaperoning does not require
structural changes associated with agonist-induced channel-
gating since the competitive antagonist (+)bicuculline is an
effective pharmacological chaperone of GABAA receptors (Eshaq
et al., 2010). Regardless of molecular mechanism(s), it is likely
that chaperoning is not required for receptor biogenesis, but
merely serves a regulatory function.
In our immunofluorescence experiments we note some
surface receptor puncta that are colocalized with GABA. While
we did not further investigate this phenomenon, we offer
several hypothetical explanations. One intriguing possibility is
that chaperoned receptors may be inserted into the plasma
membrane in a GABA-bound state. In this regard, growth
hormone receptors that are chaperoned by growth hormone are
inserted into the plasma membrane as desensitized receptor/
hormone complexes (van den Eijnden and Strous, 2007). For
the GABAA receptor to arrive at the surface as a liganded
receptor, GABA would need to be either present throughout the
secretory pathway to allow equilibrium binding/unbinding of
GABA (we have observed GABA in the Golgi by immunogold
labeling) or, alternatively, GABA might become ‘‘locked on’’
to the receptors in the secretory pathway, as is postulated
to occur when surface receptors bind GABA (Khatri et al.,
2009). For our experiments, the detection of such liganded
receptors on the surface would require that GABA remain bound
during receptor immunolabeling and subsequently be available
for antibody recognition during GABA labeling, which, while
possible, seems unlikely. More likely, due to the limited spatial
resolution of confocal microscopy, the colocalized signal may
represent receptor cell surface labeling that is in close proximity
to GABA-containing structures that are just beneath the plasma
membrane.
What might be the physiological significance of GABA acting
as a chaperone for its receptor? Many integral membrane
proteins are ‘‘inefficiently’’ processed in the RER with up
to 70% of nascent subunits/receptors degraded without being
used. These proteins include G protein-coupled receptors
(gonadotropin releasing hormone, calcium-sensing, δopioid, and
V2 vasopressin receptors), ion channels (nicotinic acetylcholine
receptors, GABAA receptors, Nav sodium channels), and growth
hormone receptors (Merlie and Lindstrom, 1983; Schmidt et al.,
1985; Gorrie et al., 1997; Janovick et al., 2002; Petäjä-Repo et al.,
2002; Wüller et al., 2004; Robert et al., 2005; Sallette et al.,
2005; Huang and Breitwieser, 2007; van den Eijnden and Strous,
2007). Interestingly, many of these wild type subunits/receptors
are not terminally misfolded since native folding, forwarding
trafficking and function can be ‘‘rescued’’ by treatment with
either pharmacological chaperones (Janovick et al., 2002; Petäjä-
Repo et al., 2002; Wüller et al., 2004; Robert et al., 2005;
Sallette et al., 2005; Huang and Breitwieser, 2007) or proteasome
inhibitors (Christianson and Green, 2004). Thus, for inefficiently
processed secretory pathway proteins, it has been suggested
that the RER serves as a storage reservoir of viable folding
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intermediates that are subject to post-translational regulatory
mechanisms (Leidenheimer and Ryder, 2014). Such a reservoir
of newly-synthesized proteins could be accessed to rapidly
increase functional pools without involving transcriptional or
translational processes. For receptors in which a large percentage
of viable proteins exist as an RER reserve pool, a modest
recruitment from the RER pool would significantly increase
the functional pool. While we have not measured GABA-gated
chloride currents in our experiments here, we note that in HEK
293 cells, GABA chaperoning of recombinant receptors results in
a concomitant increase in receptor function (Eshaq et al., 2010)
and that increased cell surface expression of the receptor is highly
correlated with larger peak amplitudeGABAA receptor responses
(Vithlani et al., 2011).
In addition to regulating to the number of surface receptors,
the chaperoning of GABAA receptors may favor the production
of certain GABAA receptor subtypes, potentially controlling the
balance of phasic:tonic GABAergic inhibition. Phasic inhibition
is a fast, transitory process that is mediated by γsubunit-
containing synaptic receptors that bind GABA with low-affinity.
Tonic inhibition is a slow, sustained process mediated by δ
subunit-containing extrasynaptic receptors that bind GABA
with high-affinity (Farrant and Nusser, 2005; Belelli et al.,
2009). These types of GABAA receptor-mediated inhibition
have unique roles in maintaining physiological processes and
contributing to various pathophysiologies. We envision two
possible mechanisms by which chaperoning could bias the
production of receptor subtypes that participate in these two
distinct modes of inhibition. First, GABA binding could favor
the incorporation of either the γ or δ subunit into the pentamer
during the assembly process. In this regard, nicotine acting as
a pharmacological chaperone prior to nicotinic acetylcholine
receptor pentamerization, biases the incorporation of a β3
subunit over an α subunit into the accessory fifth position, thus
allowing for post-translational subunit switching (Srinivasan
et al., 2011; Mazzo et al., 2013). Secondly, because GABAA
receptor subtypes have widely varying affinities for GABA
(Farrant and Nusser, 2005), it is possible that tightly-controlled
RER luminal GABA concentrations may favor the biogenesis of
high-affinity extrasynaptic GABAA receptors.
Where in the cell does chaperoning occur? The subcellular
site of GABAA receptor subunit synthesis and assembly
is not yet known, however, it is presumed to occur in
the soma as well as in dendrites (see below). While our
experiments do not address where in the neuron chaperoning
occurs, we note that GABA is present in the cell soma,
albeit at apparently lower concentrations than in dendrites.
Furthermore, our immunogold labeling detects GABA in
somatic RER in glutamatergic neurons. With respect to
dendrites, our data and those from previous immunogold-
labeling experiments (Fujiyama et al., 2000), place postsynaptic
GABAA receptors and intracellular GABA in close proximity in
dendrites, suggesting that chaperoning may occur in dendritic
compartments. In this regard, dendrites possess a prodigious
anastomosing ER (Horton and Ehlers, 2003) with over 2500
mRNAs identified in the hippocampal synaptic neuropil
including an abundance of neurotransmitter receptor mRNAs
(Cajigas et al., 2012). Indeed deep sequencing of the synaptic
neuropil transcriptome (Cajigas et al., 2012) and laser capture
microdissection of dendrites in rat motor cortex (Costa et al.,
2002) have revealed the presence of eight distinct dendritically-
localized GABAA receptor subunit mRNAs. Because of the
abundance of GABA in neuronal processes noted here
and elsewhere (Fujiyama et al., 2000) and the presumed
translation of GABAA receptor subunit mRNAs in dendrites,
we propose that GABA chaperoning targets dendritically
synthesized receptors/receptor intermediates, perhaps in close
proximity to inhibitory synapses.
The synthesis of GABA from its precursor glutamate occurs
in the cell cytoplasm catalyzed by glutamic acid decarboxylase
isoforms, GAD 65 and GAD 67 (Pinal and Tobin, 1998).
GAD65 is localized primarily to presynaptic terminals and
produces a ‘‘transmitter’’ pool of GABA. GAD 67 has a
ubiquitous central nervous system distribution and is responsible
for maintaining low millimolar concentrations of ‘‘metabolic’’
GABA in the cytosol (Otsuka et al., 1971; Rothman et al.,
1993; Pinal and Tobin, 1998; Wu et al., 2007; Lee et al., 2011).
Whether ‘‘chaperone’’ GABA is derived from ‘‘metabolic’’ and/or
‘‘transmitter’’ GABA pools remains to be determined, however,
because of the widespread cellular distribution of ‘‘metabolic’’
GABA, it is likely that at least some ‘‘chaperone’’ GABA is derived
from the metabolic pool, i.e., synthesized by GAD67. The source
of ‘‘chaperone GABA’’ is important as it will aid in determining
whether chaperoning is a cell autonomous or non-autonomous
process. The ability of GABA to be redistributed between cells
by both GAT and non-GAT transport mechanisms, into both
GABAergic and non-GABAergic neurons, as well as astrocytes
(Madsen et al., 2010; Suñol et al., 2010; Zhou and Danbolt, 2013)
will complicate efforts to characterize the source of ‘‘chaperone’’
GABA.
While the physiological significance of ‘‘metabolic’’ GABA
is not understood, it is worth noting that approximately
ninety percent of GABA in newborn mice is synthesized
via GAD67 (Asada et al., 1997), implying an important
role for ‘‘metabolic’’ GABA and GAD67 in brain function.
The observations that GAD67 protein and/or mRNA levels
increase subsequent to sensory learning (Gierdalski et al.,
2001), hippocampal kindling (Ramírez and Gutiérrez, 2001),
voluntary exercise (Hill et al., 2010), ischemia (Li et al., 2010),
and benzodiazepine discontinuation (Izzo et al., 2001) indicate
that GABA levels in the brain are dynamically regulated in
response to a wide range of stimuli. Such regulation could
be envisioned to impact GABA chaperoning by controlling
intracellular GABA concentrations. Tangentially, it has long been
recognized that GABA synthesis and degradation are linked to
the tricarboxylic acid cycle via the ‘‘GABA shunt’’, a closed-
loop circuit allowing for both the production of GABA and
the conservation of its precursor glutamate (Martin, 1993). The
relationship between the tricarboxylic acid cycle and GABA
production may potentially link GABA chaperoning of GABAA
receptors to energy metabolism.
In conclusion, our findings provide evidence that neuronal
GABAA receptors undergo cognate ligand chaperoning in the
RER by endogenous GABA. While many questions remain,
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we propose that the RER functions as a local reservoir
of receptor intermediates that allows GABA chaperoning-
dependent recruitment of nascent receptors into the functional
pool. Such a mechanism may have evolved to allow rapid and
local post-translational control over functional receptor pools
in a morphologically complex cell. Because GABA is used as
a neurotransmitter, paracrine signaling molecule, trophic factor
and energy metabolite (Pinal and Tobin, 1998), its role as a
cognate ligand chaperone may be uniquely complex.
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